Eckert & Ziegler Strahlen & Medizintechnik AG reported group earnings results for the third quarter and nine months ended September 2015. In the third quarter of 2015, however, business was moderate at the Eckert & Ziegler Group. The company reported that profit attributable to the shareholders for the third quarter ended September 30, 2015 was EUR 1.49 million, or EUR 0.28 per share, compared to EUR 2.3 million, or EUR 0.43 per share, for the same quarter ended September 30, 2014. Revenues for the third quarter ended September 30, 2015 were E33.7 million, compared to E30.63 million for the same quarter ended September 30, 2014.

The company achieved sales of EUR 102.7 million in the nine months from January to September 2015. Compared to the same period in the prior year, sales were up by EUR 10.2 million or 11%. A majority of this amount, EUR 8.3 million, is due to the more favorable US dollar /euro exchange rate. The acquisition of the Isotope Products segment in Brazil saw sales climb by EUR 2.3 million. Organic sales declined slightly by EUR 0.4 million. Due to the special income reported in the second quarter of 2015 from the disposal of the OctreoPharm Sciences GmbH investment, EBIT improved to EUR 13.8 million for the first nine months. Profit for the period after taxes and minority interests also increased sharply to EUR 9.0 million or EUR 1.70 per share compared to EUR 5.56 million, or EUR 1.05 per share, for the same period ended September 30, 2014.

The company expects sales to rise to over EUR 133 million in 2015, while an improvement in earnings to over EUR 2.00 per share.

The company expects sales to increase slightly to between EUR 137 and EUR 140 million in 2016, assuming exchange rates remain stable. Earnings per share are likely to decline to approximately EUR 1.80 per share in 2016 due to the absence of positive one-off effects.